Pfizer: positive results for meningococcal vaccine
(CercleFinance.com) - Pfizer has announced positive top-line results from the pivotal Phase 3 trial evaluating the safety, tolerability and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy people aged 10 to 25 years.
The trial met all primary and secondary endpoints.
Pfizer intends to submit a Biologics License Application to the US FDA in Q4 this year. It also plans to make submissions to other regulatory authorities outside the US.
Today, the group estimates that there are approximately 52 million adolescents and young adults eligible for meningococcal vaccination under US guidelines.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The trial met all primary and secondary endpoints.
Pfizer intends to submit a Biologics License Application to the US FDA in Q4 this year. It also plans to make submissions to other regulatory authorities outside the US.
Today, the group estimates that there are approximately 52 million adolescents and young adults eligible for meningococcal vaccination under US guidelines.
Copyright (c) 2022 CercleFinance.com. All rights reserved.